What this means
This is a planned trial that is recruiting people now, and it has not reported results yet. It will show whether fisetin might change aging cells and walking distance, but it cannot tell us if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 50 and over · 34 people with peripheral artery disease
- Where
- 1 site, including Illinois
The science
- Registered title
- Fisetin to Reduce Senescence and Mobility Impairment in PAD
- Trial ID
- NCT06399809 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty, Claudication
- What is tested
- Fisetin, Placebo
- Sponsor
- Northwestern University
- Ages
- 50 Years to no maximum
- Dates
- First posted May 6, 2024 · updated Apr 15, 2026
Registry summary
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.
Sites (1)
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States